The GHIT Fund of Japan continues their support for the development of a malaria transmission-blocking vaccine.
The GHIT Fund of Japan announced on March 31, 2021, their new investments to support global R&D projects for neglected tropical diseases. This includes new funding for a First-In-Human Trial of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1.
CellFree Sciences is most grateful for the continuous support given by the GHIT Fund for the development of an AnAPN1-based malaria transmission-blocking vaccine! In a project led by Prof. Rhoel Dinglasan at the University of Florida, we had been working together for several years on the development of an optimized antigen focusing on the transmission-blocking domain in the AnAPN1 protein. With the new GHIT funding, we will now move this new antigen to clinical development in Gabon.
We are looking forward to working together with Ajinomoto Bio-Pharma Services, GeneDesign, the Centre de Recherches Médicales de Lambaréné (CERMEL), University of Tübingen and The University of Florida to make this important project successful. It is our hope that this vaccine will in the future contribute to better malaria control and eradication.
Project description on GHIT Webpage:
